Intra-Cellular Therapies, Inc. (ITCI), Tuesday announced positive data from phase 3 trial of Lumateperone, marketed as Caplyta, for the prevention of relapse in adult patients with Schizophrenia, a chronic mental illness.
The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day.
The biopharmaceutical company found that the time to relapse during the double-blind treatment phase was significantly longer in patients receiving Lumateperone compared to those receiving placebo, which was the primary endpoint of the study.
The trial also achieved the key secondary endpoint regarding time to all cause discontinuation during the double-blind phase.
During the pre-market hours, Intra-Cellular's stock is moving up 0.96 percent, to $87 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.